NASDAQ:PRTG - Portage Biotech Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $35.00
  • Forecasted Upside: 232.07 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$10.54
▲ +0.11 (1.05%)

This chart shows the closing price for PRTG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Portage Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRTG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRTG

Analyst Price Target is $35.00
▲ +232.07% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Portage Biotech in the last 3 months. The average price target is $35.00, with a high forecast of $40.00 and a low forecast of $30.00. The average price target represents a 232.07% upside from the last price of $10.54.

This chart shows the closing price for PRTG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Portage Biotech.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/19/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/20/2021OppenheimerInitiated CoverageOutperform$30.00High
9/2/2021B. RileyInitiated CoverageBuy$40.00Low
8/19/2021Cantor FitzgeraldInitiated CoverageOverweight$35.00Low
(Data available from 1/17/2017 forward)

News Sentiment Rating

-0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
8/20/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/19/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/19/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/18/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/18/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/17/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Portage Biotech logo
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company's product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Read More

Today's Range

Now: $10.54
Low: $10.25
High: $10.77

50 Day Range

MA: $14.24
Low: $10.43
High: $22.82

52 Week Range

Now: $10.54
Low: $10.00
High: $44.98

Volume

43,483 shs

Average Volume

19,080 shs

Market Capitalization

$140.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Portage Biotech?

The following Wall Street research analysts have issued stock ratings on Portage Biotech in the last year: B. Riley, Cantor Fitzgerald, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for PRTG.

What is the current price target for Portage Biotech?

3 Wall Street analysts have set twelve-month price targets for Portage Biotech in the last year. Their average twelve-month price target is $35.00, suggesting a possible upside of 232.1%. B. Riley has the highest price target set, predicting PRTG will reach $40.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $30.00 for Portage Biotech in the next year.
View the latest price targets for PRTG.

What is the current consensus analyst rating for Portage Biotech?

Portage Biotech currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRTG will outperform the market and that investors should add to their positions of Portage Biotech.
View the latest ratings for PRTG.

How do I contact Portage Biotech's investor relations team?

Portage Biotech's physical mailing address is Craigmuir Chambers Road Town, Tortola D8, VG1110. The company's listed phone number is 416-929-1806. The official website for Portage Biotech is www.portagebiotech.com.